Risk of adverse drug events by patient destination after hospital discharge

American Journal of Health-System Pharmacy

Volumn 62, Issue 18, 2005, Pages 1883-1889

  Triller, Darren M ^a   Clause, Steven L ^b   Hamilton, Robert A ^c  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Deparment of Pharmacy   (Marshall Islands)

^c Deparment of Pharmacy   (United States)

Author keywords

Ambulatory care; Cardiac drugs; Cognition disorders; Drugs, adverse reactions; Health care; Heart failure; Hypoproteinemia; Long term care facilities; Psychotherapeutic agents; Rational therapy; Reports

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIURETIC AGENT; NEUROLEPTIC AGENT; POTASSIUM DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ADVERSE DRUG REACTION; ARTICLE; COGNITIVE DEFECT; DRUG USE; FEMALE; HEART FAILURE; HOME CARE; HOSPITAL DISCHARGE; HUMAN; HYPOALBUMINEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PRIORITY JOURNAL; RISK ASSESSMENT; SELF CARE;

EID: 24944541425     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040537     Document Type: Article

References (58)

1. Flynn EA, Barker KN, Carnahan BJ. National observational study of prescription dispensing accuracy and safety in 50 pharmacies. J Am Pharm Assoc. 2003; 43:191-200.
2. Kaufman DW, Kelly JP, Rosenberg L et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA. 2002; 287:337-44.
3. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Pub. L. 108-173 (2003).
4. Gray SL, Mahoney JE, Blough DK. Adverse drug events in elderly patients receiving home health services following hospital discharge. Ann Pharmacother. 1999; 33:1147-53.
5. Hanlon JT, Shimp LA, Semla TP. Recent advances in geriatrics: drug-related problems in the elderly. Ann Pharmacother. 2000; 34:360-5.
6. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003; 289:2560-72.
7. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the Advisory Council To Improve Outcomes Nationwide in Heart Failure. Am J Cardiol. 1999; 83:1A-38A.
8. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2001; 24(suppl 1):S33-43.
9. Wassertheil-Smoller S, Hendrix SL, Limacher M et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003; 289:2673-84.
10. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human: building a safer health system. Washington, DC: National Academy Press; 1999:xvi,223.
11. Bates DW, Cullen DL, Laird NM et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group. JAMA. 1995; 274:29-34.
12. Forster AJ, Murff HJ, Peterson JF et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138:161-7.
13. Graves T, Hanlon JT, Schmader KE et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997; 157:2205-10.
14. Leape LL, Brennan TA, Laird NM et al. The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. N Engl J Med. 1991; 324:377-84.
15. Brennan TA, Leape LL, Laird NM et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991. Qual Saf Health Care. 2004; 13:145-52.
16. Strand LM, Morley PC, Cipolle RJ et al. Drug-related problems: their structure and function. DICP Ann Pharmacother. 1990; 24:1093-7.
17. Gurwitz JH, Field TS, Avorn J et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med. 2000; 109:87-94.
18. Gurwitz JH, Field TS, Harrold LR et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA. 2003; 289:1107-16.
19. Hanlon JT, Schmader KE, Koronkowski MJ et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997; 45:945-8.
20. Cullen DJ, Schweitzer BJ, Bates DW et al. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit Care Med. 1997; 25:1289-97.
21. Institute of Medicine (U.S.) Committee on Quality of Health Care in America. Priority areas for national action: transforming health care quality. Washington, DC: National Academy Press; 2003.
22. Flynn EA, Barker KN, Pepper GA et al. Comparison of methods for detecting medication errors in 36 hospitals and skilled-nursing facilities. Am J Health-Syst Pharm. 2002; 59:436-46.
23. Leape LL, Bates DW, Cullen DJ et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995; 274:35-43.
24. Medication management standards (MM). Oakbrook Terrace, IL: Joint Commission on Accreditation of Healthcare Organizations; 2004.
25. Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet 1998; 351:643-4.
26. Phillips J, Beam S, Brinker A et al. Retrospective analysis of mortalities associated with medication errors. Am J Health-Syst Pharm. 2001; 58:1835-41.
27. Triller DM, Clause SL, Briceland LL et al. Resolution of drug-related problems in home care patients through a pharmacy referral service. Am J Health-Syst Pharm. 2003; 60:905-10.
28. Golden AG, Preston RA, Barnett SD et al. Inappropriate medication prescribing in homebound older adults. J Am Geriatr Soc. 1999; 47:948-53.
29. Dennehy CE, Kishi DT, Louie C. Drug-related illness in emergency department patients. Am J Health-Syst Pharm. 1996; 53:1422-6.
30. Bates DW, Evans DW, Murff H et al. Detecting adverse events using information technology. J Am Med Inform Assoc. 2003; 10:115-28.
31. Fick DM, Cooper JW, Wade WE et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med. 2003; 163:2716-24.
32. Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997; 157:1531-6.
33. Anderson GM, Beers MH, Kerluke K. Auditing prescription practice using explicit criteria and computerized drug benefit claims data. J Eval Clin Pract. 1997; 3:283-94.
34. Honigman B, Lee J, Rothschild J et al. Using computerized data to identify adverse drug events in outpatients. J Am Med Inform Assoc. 2001; 8:254-66.
35. Cooper JW Jr, Bagwell CG. Contribution of the consultant pharmacist to rational drug usage in the long-term care facility. J Am Geriatr Soc. 1978; 26:513-20.
36. Hatoum HT, Hutchinson RA, Witte KW et al. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988; 22:252-9.
37. Johnson JA, Bootman JL. Drug-related morbidity and mortality and the economic impact of pharmaceutical care. Am J Health-Syst Pharm. 1997; 54:554-8.
38. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
39. Triller DM, Clause SL, Domarew C. Analysis of medication management activities for home-dwelling patients. Am J Health-Syst Pharm. 2002; 59:2356-9.
40. Triller DM, Miller MT, Briceland LL et al. Trovafloxacin-associated exfoliative dermatitis in a homecare patient. Ann Pharmacother. 1999;33:1122.
41. Meredith S, Feldman PH, Frey D et al. Possible medication errors in home healthcare patients. J Am Geriatr Soc. 2001; 49:719-24.
42. Clause SL, Triller DM. Problem with nebulized medications in a home health care patient. Am J Health-Syst Pharm. 2002; 59:1462-3.
43. Backo AL, Clause SL, Triller DM et al. Clonidine-induced hypertension in a patient with a spinal lesion. Ann Pharmacother. 2002; 36:1396-8.
44. Bates DW, Miller EB, Cullen DJ et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med. 1999; 159:2553-60.
45. Van den Bemt PM, Egberts AC, Linderink AW et al. Risk factors for the development of adverse drug events in hospitalized patients. Pharm World Sci. 2000; 22:62-6.
46. Field TS, Gurwitz JH, Avorn J et al. Risk factors for adverse drug events among nursing home residents. Arch Intern Med., 2001; 161:1629-34.
47. Moore N, Lecointre D, Noblet C et al. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J Clin Pharmacol. 1998; 45:301-8.
48. Rothschild JM, Federico FA, Gandhi TK et al. Analysis of medication-related malpractice claims: causes, preventability, and costs. Arch Intern Med. 2002; 162:2414-20.
49. Peyriere H, Cassan S, Floutard E et al. Adverse drug events associated with hospital admission. Ann Pharmacother. 2003; 37:5-11.
50. Marinella MA, Markert RJ. Admission serum albumin level and length of hospitalization in elderly patients. South Med J. 1998; 91:851-4.
51. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36:1331-6.
52. Winterstein AG, Hatton RC, Gonzalez-Rothi R et al. Identifying clinically significant preventable adverse drug events through a hospital's database of adverse drug reaction reports. Am J Health-Syst Pharm. 2002; 59:1742-9.
53. Chu LW, Pei CK. Risk factors for early emergency hospital readmission in elderly medical patients. Gerontology. 1999; 45:220-6.
54. Clause SL, Triller DM, Borhhorst CP et al. Conforming to HIPAA regulations and compilation of research data. Am J Health-Syst Pharm. 2004; 61:1025-31.
55. Miller DA, Lucarotti RL, Vlasses PH et al. Perceived clinical significance of consultant pharmacist recommendations in the skilled nursing facility. Drug Intell Clin Pharm. 1980; 14:182-6.
56. McGhan WF, Wertheimer AI, Marttila JK. Assessing the need for pharmacist-conducted drug regimen reviews in skilled nursing and intermediate care facilities. Contemp Pharm Pract. 1980; 3:203-9.
57. Gattis WA, Hasselblad V, Whellan DJ et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med. 1999; 159:1939-45.
58. Stewart S, Vanderbroek AJ, Pearson S et al. Prolonged beneficial effects of a home-based intervention on unplanned readmissions and mortality among patients with congestive heart failure. Arch Intern Med. 1999; 159:257-61.